Tarcocimab in RVO: uniquely poised to address the core unmet need in RVO with high efficacy and best-in-class durability Quadrant of core unmet need RVO: retinal vein occlusion; BRVO: branched retinal vein occlusion; 1. Durability interval calculated based on patients that received no injections (46%) or 1 injection (29%) over the second 6 months of Year 1. 2. RVO market size from imarc: RVO Market Size, Epidemilogy, In-Market drug sales, pipeline therapies, and Regional Outlook 0% 10% 20% 30% 40% 50% 1 2 3 4 5 6 7 8 9 10 11 Tarcocimab BRVO Tarcocimab All RVO Aflibercept BRVO Aflibercept All RVO Number of injections through Year 1 Proportion of subjects Tarcocimab 78% received ≤ 5 doses Aflibercept 93% received ≥ 6 doses Tarcocimab Number of doses in the second 6 months of Year 1 0-1 doses 75% 2 doses 18% 4-6 doses 2% 3 doses 5% 6-month durability 75% 1 Gen 1.5 agents have failed to address the key unmet need for high efficacy with better durability in RVO. With built-in durability, tarcocimab delivered 6-month durability in 75% of RVO patients in BEACON and is uniquely poised to address key unmet needs for RVO patients RVO market size: ~$3B 27